Dr. Lal Pathlabs

** Shares of Dr Lal PathLabs DLPA.NS rise as much as 1.3% to 1,986.80 rupees

** Diagnostics co will acquire a 70% stake in genomics-focused SN Genelab for 1.68 billion rupees ($17.52 million), plus up to 315 million rupees in performance-linked payouts

** Emkay raises PT to 2,100 rupees from 2,000 rupees, maintains "Buy"

** Emkay sees acquisition expanding DLPA's advanced genomics and molecular pathology portfolio, while offering cross-selling opportunities and geographic diversification

** Nomura ("Buy", PT: 2,150 rupees) sees marginal near-term earnings-per-share dilution from acquisition, but significant long-term upside as SN Genelab's testing capabilities scale through Dr Lal's network

** Twenty-five analysts have a "buy" rating; median PT is 2,025 rupees -- data compiled by LSEG

** YTD, DLPA up 30%

($1 = 95.9100 Indian rupees)

(Reporting by Urvi Dugar in Bengaluru)

(([email protected];))

Dr Lal PathLabs' board approved the acquisition of a 70% stake in SN Genelab Private Limited for cash consideration of up to Rs 168 crore plus a performance-linked earnout capped at Rs 31.5 crore, with completion targeted by 30 November 2026. SN Genelab, incorporated in Gujarat in December 2013, provided diagnostics-genomics services and reported turnover of Rs 57.96 crore in the year to March 2026, up from Rs 43.27 crore in FY24. Recent bolt-on outlays included a Mumbai laboratory acquisition and a Rs 3.5 crore subscription for a 30% stake in Neuome Technologies completed in August. The company reported revenue of Rs 2,763 crore for the year to March 2026 and held net cash of Rs 1,526 crore. Its core business remained pathology-led and B2C-heavy, where bundled SwasthFit tests accounted for about 26% of revenue.

Powered by Tijori

Aug 19 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• SUBSIDIARY INCORPORATED DR LAL PATHLABS INDOMED IN TASHKENT, UZBEKISTAN

Source text: ID:nBSE7GkR8l

Further company coverage: DLPA.NS

(([email protected];;))

July 24 (Reuters) - Indian diagnostics firm Dr Lal PathLabs DLPA.NS on Friday reported a rise in first-quarter profit, boosted by sustained demand for its tests and preventive health packages under the SwasthFit banner.

Here are more details:

• Consolidated net profit for the three months ended June 30 rose to 1.70 billion rupees ($17.62 million) from 1.32 billion rupees a year earlier.

• Analysts said the company is expected to see favorable tailwinds from its growth in bundled test packages, setting up of new precision diagnostic centers, and a continued focus on improving its revenue per patient.

• Dr Lal, which operated 312 clinical labs as of March 31, reported a 19% increase in consolidated revenue from operations to 7.98 billion rupees during the quarter.

• The company is aggressively adding more labs to its network, and the management in the previous quarter said that it expected margins to be between 27% and 28% in the current fiscal as it steps up investments.

• The company's board also approved the acquisition of stakes in Ghana-based diagnostic imaging company Sunshine Healthcare for 380 million rupees and in Bengaluru-based biotechnology and diagnostics startup Neuome Technologies for 35 million rupees.

• India's diagnostic chains continue to benefit from growing demand for preventive healthcare and routine health screening and chronic disease management as consumers increasingly opt for organised networks over standalone players.

• The board approved an interim dividend of 5 rupees per equity share for FY26-27.

($1 = 96.4675 Indian rupees)

(Reporting by Saikeerthi in Bengaluru; Editing by Sonia Cheema)

(([email protected]; (+91) 8296756080))

July 17 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS - RECEIVES APPELLATE ORDER FROM TAX DEPARTMENT ALLOWING APPEAL

• LAL PATHLABS - DEDUCTION OF 326.6 MILLION RUPEES FOR ESOP EXPENSES ALLOWED

Source text: ID:nBSE6RJk7s

Further company coverage: DLPA.NS

(([email protected];))

** Shares of India's Lal PathLabs DLPA.NS jump 18.58% to 1,621.20 rupees, on course for best day ever, if gains hold

** Diagnostics firm's Q4 revenue rose 16.6% y/y, aided by growth in sample volumes, higher patient additions

** Phillip Capital ("buy", PT: 1,800 rupees) raises FY27 and FY28 earnings estimates by 2% and 7%, respectively, on better-than-expected revenue guidance

** ICICI Securities cuts PT by 40 rupees to 1,460 rupees; estimates 13% revenue and 14.2% EBITDA CAGR over FY26–FY28

** Cuts FY27 and FY28 PAT estimates by ~1% and ~3%, respectively, citing near-term margin pressure from expansion investments

** Trading vols at 2.3 mln shares, nearly 7x the 30-day average

** YTD, stock up ~1.5%

($1 = 94.8687 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

April 30 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS MARCH-QUARTER CONSOL NET PROFIT 1.31 BILLION RUPEES

• LAL PATHLABS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.03 BILLION RUPEES

• LAL PATHLABS - RECOMMENDS FINAL DIVIDEND OF 4 RUPEES PER SHARE FOR FY2026

Further company coverage: DLPA.NS

(([email protected];))

** Citi Research upgrades Dr Lal PathLabs DLPA.NS to “buy” from “sell”, raises PT to 1,650 rupees from 1,450 rupees

** Brokerage says India’s diagnostics sector moved past COVID-era price wars to more rational competition

** Says diagnostics firm has maintained pricing discipline with no broad hikes despite competition from standalone labs/hospitals

** Expects co to deliver ~10–12% organic revenue growth during FY26-28, driven by core market gains, tier-3/4 cities expansion, richer mix of specialty offerings

** Says margins should remain strong at 28–29%, supported by operating leverage, cost control, supply chain efficiencies

** Robust, debt-free balance sheet supports growth, acquisitions; recent stock correction makes valuations attractive - Citi

** Stock last down 1.8% to 1321 rupees in broader weak market; down 10.9% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Jan 30 (Reuters) - Dr. Lal Path Labs DLPA.NS reported a lower third-quarter profit on Friday after taking a one-time charge linked to India’s new labour code, despite strong demand for its bundled test packages.

Consolidated net profit fell to 905 million rupees ($9.85 million) in the quarter ended December 31, from 967 million rupees a year earlier.

The country's largest diagnostics firm by revenue took up a one-time charge worth 301 million rupees linked to India's new labour codes.

India's new labour codes - the country's biggest overhaul of workers' laws in decades - have dragged profits of large corporates, including those of Godrej Consumer Products GOCP.NS, Wipro WIPR.NS and Infosys INFY.NS.

Excluding the charge, profit rose nearly 12% to 1.54 billion rupees.

Dr. Lal, which operates about 300 clinical labs across India, saw an 7.8% rise in sample volume in the reported quarter, taking its total revenue from operations nearly 11% higher to 65.98 billion rupees.

Rising focus on preventive healthcare, coupled with diagnostics chains such as Dr Lal PathLabs expanding into smaller cities, has boosted demand for medical tests, particularly in urban markets.

The company also gained from strong uptake of its bundled test packages, which group screenings for multiple conditions, including diabetes and thyroid disorders, into a single offering.

($1 = 91.8890 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected]; 8800437922;))

Oct 24 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS - CONSIDER ISSUANCE OF BONUS SHARES

Source text: ID:nBSE2R2BZF

Further company coverage: DLPA.NS

(([email protected];;))

** India reducing tax on all medicines from 12% to 5% is a positive move for pharma firms, enabling lower prices and boosting margins by 1%–2%, CLSA notes

** CLSA identifies Torrent Pharma TORP.NS, Abbott India ABOT.NS, Cipla CIPL.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Sun Pharma SUN.NS as key beneficiaries

** All shares currently trading flat

** Medical equipment such as diagnostic kits, blood glucose monitors, surgical devices and bandages will be taxed at 5% from 12% earlier

** CLSA says cut will be positive for diagnostics chains like Dr Lal Pathlabs DLPA.NS, also marginally positive for hospital chains; CLSA's top pick is Apollo Hospitals APLH.NS

** DLPA, APLH rise 1.2% and 1.8%, respectively

** YTD, all stocks rise except Lupin and Sun, which have fallen ~18% and 16.7%, respectively vs pharma index's .NIPHARM 6.5% decline

(Reporting by Urvi Dugar)

(([email protected]))

** Shares of diagnostic services provider Dr Lal PathLabs DLPA.NS rise 4% to 2,900 rupees

** Co's fourth-quarter net profit jumps 83.2% y/y to 1.55 billion rupees (about $18 million), beating avg estimate of 1.02 billion rupees, per data compiled by LSEG

** DLPA sees strong demand for bundled test offerings, amid rising health and wellness awareness in India

** DLPA's quarterly revenue rises 10.5% y/y to 6.03 bln rupees, led by 9.5% y/y rise in sample volume

** Stock sees fifth straight session of gains

** Including session's gains, DLPA up 25.5% in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

April 15 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS LTD - LAUNCHES ADVANCED TEST FOR AMYLOIDOSIS

Source text: ID:nNSEsZfqN

Further company coverage: DLPA.NS

(([email protected];))

** Shares of Metropolis Healthcare Ltd METP.NS rise 4.4% to 1,813.75 rupees

** Medical diagnostics firm reported a 15.5% rise in Q3 profit on higher sales of costlier tests after market hours on Tuesday; rev up 10%

** METP and larger rival Dr Lal PathLabs DLPA.NS rated "Hold", while analysts rate smaller rival Vijaya Diagnostic VIJA.NS "Buy" - LSEG

** Stock trims YTD losses to 12.8%, but trails DLPA's ~7% loss and VIJA's 11% climb this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Dr. Lal Pathlabs DLPA.NS rise 3.5% to 2,86.1 rupees

** The diagnostics firm posted a 19% rise in Q3 consol net profit to 967 mln rupees ($11.2 mln); rev from ops up 11% Y/Y

** Profit aided by strong volume growth through expansion in core markets and in newer regions of west and south

** More than 812,000 shares change hands, 3.3x its 30-day avg

** 20 analysts covering the stock on avg have a "hold" rating; median PT is 3,310 rupees - LSEG data

** Stock gained 16% in 2024

($1 = 86.5700 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Dec 19 (Reuters) - Max India Ltd MAII.NS:

• ANTARA SENIOR CARE ANNOUNCES STRATEGIC COLLABORATION WITH DR. LAL PATHLABS

• PARTNERSHIP TO JOINTLY OFFER DIAGNOSTIC SERVICES TO SENIORS

Source text: ID:nBSEb848Lc

Further company coverage: MAII.NS

(([email protected];;))

Oct 23 (Reuters) - Dr. Lal PathLabs DLPA.NS, India's top diagnostics firm by revenue, reported a bigger-than-expected second-quarter profit on Wednesday, driven by continued demand and a rising awareness for health and wellness.

The company's consolidated net profit increased 18% year-over-year to 1.29 billion rupees ($15.4 million), increasing for the sixth quarter in a row.

That beat analysts' estimates of 1.26 billion rupees, according to estimates compiled by LSEG.

The company, which operates about 300 labs in India, said the number of samples it tested climbed 10% and that it is building back volumes.

Analysts said awareness regarding health and wellness is rising in the country and, along with Dr. Lal PathLabs' expansion into smaller cities, is boosting demand for medical tests. They also said the company is expected to benefit from price hikes.

However, Dr. Lal PathLabs did not specify if it raised prices of its tests.

The company's revenue from operations increased 10% to 6.6 billion rupees, beating analysts' estimates of 6 billion rupees.

Rival Metropolis Healthcare METP.NS is yet to report its September quarter results.

($1 = 84.0490 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of pathology services provider Dr. Lal Pathlabs DLPA.NS close up 0.4% at 3,311 rupees

** Nomura flags relatively fewer dengue cases in Jan-Sept, particularly in Delhi NCR which accounted for almost a third of DLPA's FY24 revenue

** Number of dengue cases in Delhi in the period was less than half of last year, Nomura said, citing news channel ABP live

** DLPA Q2 earnings due on Wednesday; Nomura expects Q2 revenue to rise 10.5% Y/Y, slower than the 11.3% growth in Q1

** Historically, co's Q2 rev growth is higher than Q1, brokerage says

** Nomura rates DLPA 'buy' with Sept 2025 TP of 3,720 rupees

** Stock up ~29% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Sept 19 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS - KENYA UNIT HAS BEEN DISSOLVED

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

(([email protected];))

Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS- VED PRAKASH GOEL DESIGNATED AS GROUP CHIEF FINANCIAL OFFICER

Source text for Eikon: ID:nNSEbMbNht

Further company coverage: DLPA.NS

Aug 7 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• Q1 CONSOL NET PROFIT 1.06 BILLION RUPEES; IBES PROFIT EST. 992.7 MILLION RUPEES

• Q1 CONSOL REVENUE FROM OPERATIONS 6.02 BILLION RUPEES; IBES EST. 6.03 BILLION RUPEES

• DECLARED DIVIDEND OF 6 RUPEES PER SHARE

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

(([email protected];))

** Shares of Thyrocare Technologies THYO.NS gain 10% in heavy trading, set for third straight session of gain

** Diagnostics firm reported ~40% Y/Y climb in Q1 consol net profit on strong testing demand; rev from ops climbed 16% Y/Y

** Trading volume more than 8x the 30-day moving average

** Stock up 11% YTD vs bigger rival Dr. Lal PathLabs' DLPA.NS ~17% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Dr. Lal PathLabs DLPA.NS up 6.04% to 2,489.8 rupees - its highest since early Feb.

** At least eight brokerages up TPs on stock post Friday's Q4 profit rise, including Nomura - LSEG

** Stock settled 5.2% higher in the previous session

** Nomura upgrades rating on stock to "Buy" from "Neutral" reflecting improved growth visibility, limited downside risks in valuation of stock

** Raises FY25-26 earnings estimates by 6%-8% on higher rev, gross margin and operating leverage

** Morgan Stanley keeps TP of 2,681 rupees and rating "Overweight" unchanged

** Prefers DLPA for its strong execution record, remains cautious on patient growth and tests/patients trajectory

** Analysts avg rating on stock is "Hold", their median PT on stock is 2,600 rupees

** Stock down 3.4% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

BENGALURU, May 10 (Reuters) - Dr. Lal PathLabs DLPA.NS, India's biggest diagnostics firm by revenue, posted a bigger profit for the fourth straight quarter on Thursday, led by the addition of more labs and increased demand for medical tests.

The company's consolidated net profit jumped 49% year-on-year to 845 million rupees ($10.1 million) in the fourth quarter.

Its shares climbed as much as 7.8% after the results before trimming some gains to trade up about 6%. Rival Metropolis Healthcare METP.NS was up about 2% and Thyrocare Technologies THYO.NS gained about 1%.

Analysts expect Indian diagnostic firms to benefit from geographic expansions and price hikes.

"We're expanding our reach in core markets by strengthening our presence in Tier 3 and Tier 4 towns," Dr. Lal PathLabs Chief Executive Officer-designate Shankha Banerjee said.

The number of samples tested grew 8.5% during the quarter, and was up roughly 10% for the fiscal year.

The company, which operates more than 280 labs in India, said total revenue climbed by 11% to 5.45 billion rupees.

Thyrocare is scheduled to report its fourth-quarter results next week.

($1 = 83.4872 Indian rupees)

(Reporting by Kashish Tandon and Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of Metropolis Healthcare METP.NS rise as much as 7.4% to 1,933.50 rupees, highest since May 18, 2022

** Diagnostic services co says revenue grew ~15% Y/Y in Q4FY24

** Adds, EBITDA margins show consistent upward trend both Q/Q and Y/Y, driven by higher volumes, price increase

** Stock on track to gain for fifth straight session

** More than 1.6 mln shares traded as of 10:51 a.m. IST, 5.6x their 30-day moving avg; busiest day yet since Feb. 6

** Mean rating of 13 analysts is "hold"; median PT 1,670 rupees, while bigger peer Dr. Lal Pathlabs DLPA.NS is "sell" - LSEG data

** METP last up 4.3%, adding to YTD gains of ~11.9%; DLPA down 8%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

April 1 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• GOT ASSESSMENT ORDER WHEREIN DEDUCTION CLAIMED ON ACCOUNT OF ESOP EXPENSES OF 326.6 MILLION RUPEES DISALLOWED

Source text for Eikon: ID:nNSE6yZLrB

Further company coverage: DLPA.NS

(([email protected];;))

** Dr. Lal PathLabs' shares DLPA.NS jump 5% to 2,236 rupees

** Stock set for its steepest pct rise since early Nov

** Kotak Institutional Equities double upgrades to "add" from "sell", lifts fair value to 2,360 rupees from 1,975 rupees

** Brokerage expects improvement in pricing trends for diagnostics and views new CEO appointment as a positive

** Stock tumbled ~13% in 9 sessions since CEO left on March. 4; but has clawed back losses to ~9% since a new CEO was named on March 17

** Still, Kotak's new FV is 3.8% discount to analysts' median PT, per LSEG data

** Analysts avg rating on DLPA is "sell", while it is "hold" for peers Dr. Reddy's Labs REDY.NS and Metropolis Healthcare METP.NS

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of diagnostic services provider Dr. Lal Pathlabs DLPA.NS edge up 0.4%

** UBS analysts say co has potential to beat management's EBITDA margin guidance of 26%-27%

** Believes it would reinvest any additional margins into growth opportunities

** DLPA currently has 9 bln rupees in cash; UBS estimates co to report 33% CAGR to 28 bln rupees by FY28

** "Believe Lal Pathlabs has potential to increase EBITDA margin 250-300 basis points in same period if it maintains current rate of investment" - UBS

** Also expects steady pricing environment to aid in steady margins and revenue growth

** UBS maintains "buy" rating and target price at 2,900 rupees
** Avg recommendation on stock is a "sell;" the median TP is 2,452 rupees as per LSEG data

** DLPA is up nearly 3% so far this week, set to snap four straight weeks of losses

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

March 18 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS - GETS TAX DEMAND OF 26.3 MILLION RUPEES

Source text for Eikon: ID:nBSE3Ww5CL

Further company coverage: DLPA.NS

(([email protected];))